# Efficacy and Safety of Tirzepatide for Weight Management

Study · id `cardio:ct-nct06918405` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06918405](<https://clinicaltrials.gov/study/NCT06918405>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06918405

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 440 participants.

## Technical summary

Registry record NCT06918405. Allocation not applicable; no masking; primary purpose treatment. Start 2025-01-01 (actual); primary completion 2026-06-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 440 participants (planned count; ClinicalTrials.gov record NCT06918405, source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)
- Started: 2025-01-01 (actual) (ClinicalTrials.gov record NCT06918405, source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)
- Primary completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06918405, source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)
- Completion: 2026-06-30 (anticipated) (ClinicalTrials.gov record NCT06918405, source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)
- Countries: Bangladesh (ClinicalTrials.gov record NCT06918405, source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06918405-2025-04-09`, retrieved 2026-10-26)

## The registry's words

- Brief title: Efficacy and Safety of Tirzepatide for Weight Management
- Condition: Obesity and Obesity-related Medical Conditions
- Intervention (Drug): Tirzepatide
- Lead sponsor: Chittagong Medical College
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record: Tirzepatide (`cardio:tirzepatide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)

## Provenance

Content hash: f046c12af90c0ecc2600e831a5e487ee072a0d97b4e562ce8e5ccc14fd9e8071
Last substantive edit: 2026-10-31
Evidence last checked: Not recorded
